These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25883396)

  • 21. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.
    Largent EA; Pearson SD
    Hastings Cent Rep; 2012; 42(1):27-34. PubMed ID: 22616398
    [No Abstract]   [Full Text] [Related]  

  • 24. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of rare diseases.
    Walshe JM
    QJM; 2006 Feb; 99(2):123-4. PubMed ID: 16428334
    [No Abstract]   [Full Text] [Related]  

  • 26. Orphan drugs revisited.
    McCabe C; Tsuchiya A; Claxton K; Raftery J
    QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
    [No Abstract]   [Full Text] [Related]  

  • 27. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
    Wonder M; Chin G
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PPPs succeeding in tackling neglected diseases.
    Frantz S
    Nat Rev Drug Discov; 2005 Oct; 4(10):796-7. PubMed ID: 16237841
    [No Abstract]   [Full Text] [Related]  

  • 29. Big pharma moves from 'blockbusters' to 'niche busters'.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):837. PubMed ID: 20689537
    [No Abstract]   [Full Text] [Related]  

  • 30. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 31. Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
    Sheehan M
    BMJ; 2005 Nov; 331(7525):1144-5. PubMed ID: 16282416
    [No Abstract]   [Full Text] [Related]  

  • 32. The many vs. the few.
    Zallen DT
    Hastings Cent Rep; 2012; 42(5):4-5; author reply 8-9. PubMed ID: 22976402
    [No Abstract]   [Full Text] [Related]  

  • 33. Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
    Marshall T
    BMJ; 2005 Nov; 331(7525):1144. PubMed ID: 16282417
    [No Abstract]   [Full Text] [Related]  

  • 34. The many vs. the few.
    McCabe C
    Hastings Cent Rep; 2012; 42(5):6-7; author reply 8-9. PubMed ID: 23050291
    [No Abstract]   [Full Text] [Related]  

  • 35. Orphan drugs: expensive yet necessary.
    Hyry HI; Roos JC; Cox TM
    QJM; 2015 Apr; 108(4):269-72. PubMed ID: 25434052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
    Moran M
    PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EU to review rare disease drugs market exclusivity.
    Sheridan C
    Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
    [No Abstract]   [Full Text] [Related]  

  • 39. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
    Morrell L; Wordsworth S; Fu H; Rees S; Barker R
    BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.